KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $368.7 million.

  • Biomarin Pharmaceutical's Cash from Operations rose 6646.35% to $368.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $914.0 million, marking a year-over-year increase of 12039.63%. This contributed to the annual value of $572.8 million for FY2024, which is 25969.14% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Cash from Operations stood at $368.7 million, which was up 6646.35% from $185.3 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Cash from Operations peaked at $368.7 million during Q3 2025, and registered a low of -$73.9 million during Q1 2023.
  • Moreover, its 5-year median value for Cash from Operations was $97.1 million (2021), whereas its average is $102.2 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Cash from Operations skyrocketed by 84708.44% in 2021, and later crashed by 14002.31% in 2022.
  • Biomarin Pharmaceutical's Cash from Operations (Quarter) stood at $11.2 million in 2021, then crashed by 39.3% to $6.8 million in 2022, then surged by 305.0% to $27.5 million in 2023, then surged by 575.42% to $185.6 million in 2024, then soared by 98.62% to $368.7 million in 2025.
  • Its Cash from Operations stands at $368.7 million for Q3 2025, versus $185.3 million for Q2 2025 and $174.4 million for Q1 2025.